Search

Your search keyword '"Wali, Bushra"' showing total 165 results
Start Over Author "Wali, Bushra"
165 results on '"Wali, Bushra"'

1. Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Author

Gagne, Matthew, Flynn, Barbara J., Andrew, Shayne F., Marquez, Josue, Flebbe, Dillon R., Mychalowych, Anna, Lamb, Evan, Davis-Gardner, Meredith E., Burnett, Matthew R., Serebryannyy, Leonid A., Lin, Bob C., Ziff, Zohar E., Maule, Erin, Carroll, Robin, Naisan, Mursal, Jethmalani, Yogita, Pessaint, Laurent, Todd, John-Paul M., Doria-Rose, Nicole A., Case, James Brett, Dmitriev, Igor P., Kashentseva, Elena A., Ying, Baoling, Dodson, Alan, Kouneski, Katelyn, O’Dell, Sijy, Wali, Bushra, Ellis, Madison, Godbole, Sucheta, Laboune, Farida, Henry, Amy R., Teng, I-Ting, Wang, Danyi, Wang, Lingshu, Zhou, Qiong, Zouantchangadou, Serge, Van Ry, Alex, Lewis, Mark G., Andersen, Hanne, Kwong, Peter D., Curiel, David T., Roederer, Mario, Nason, Martha C., Foulds, Kathryn E., Suthar, Mehul S., Diamond, Michael S., Douek, Daniel C., and Seder, Robert A.

Published
2024
Full Text
View/download PDF

3. Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Author

Gagne, Matthew, Flynn, Barbara J., Honeycutt, Christopher Cole, Flebbe, Dillon R., Andrew, Shayne F., Provost, Samantha J., McCormick, Lauren, Van Ry, Alex, McCarthy, Elizabeth, Todd, John-Paul M., Bao, Saran, Teng, I-Ting, Marciano, Shir, Rudich, Yinon, Li, Chunlin, Jain, Shilpi, Wali, Bushra, Pessaint, Laurent, Dodson, Alan, Cook, Anthony, Lewis, Mark G., Andersen, Hanne, Zahradník, Jiří, Suthar, Mehul S., Nason, Martha C., Foulds, Kathryn E., Kwong, Peter D., Roederer, Mario, Schreiber, Gideon, Seder, Robert A., and Douek, Daniel C.

Published
2024
Full Text
View/download PDF

5. Durability of immune responses to mRNA booster vaccination against COVID-19

Author

Arunachalam, Prabhu S., Lai, Lilin, Samaha, Hady, Feng, Yupeng, Hu, Mengyun, Hui, Harold Sai-yin, Wali, Bushra, Ellis, Madison, Davis-Gardner, Meredith E., Huerta, Christopher, Bechnak, Kareem, Bechnak, Sarah, Lee, Matthew, Litvack, Matthew B., Losada, Cecilia, Grifoni, Alba, Sette, Alessandro, Zarnitsyna, Veronika I., Rouphael, Nadine, Suthar, Mehul S., and Pulendran, Bali

Subjects
Comirnaty (Vaccine) -- Physiological aspects -- Comparative analysis, Spikevax (Vaccine) -- Comparative analysis -- Physiological aspects, Physiological aspects, Comparative analysis, Health aspects, COVID-19 vaccines -- Physiological aspects, Secondary immunization -- Physiological aspects, Immune response -- Health aspects -- Physiological aspects
Abstract

Introduction Recent studies have shown the declining efficacy of the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA1273) mRNA vaccines after primary and booster vaccinations (1, 2). Although the booster vaccination (third dose) [...], BACKGROUND. Maintaining durable immunity following vaccination represents a major challenge, but whether mRNA booster vaccination improves durability is unknown. METHODS. We measured antibody responses in 55 healthy adults, who received a booster dose of the Pfizer-BioNTech or Moderna vaccine against SARS-CoV-2 and calculated the half-life of the antibody titers. We also measured memory B and T cell responses in a subset of 28 participants. In 13 volunteers who received a second booster vaccine, we measured serum antibody titers and memory B and T cell responses. RESULTS. The booster (third immunization) dose at 6 to 10 months increased the half-life of the serum-neutralizing antibody (nAb) titers to 76 days from 56 to 66 days after the primary 2-dose vaccination. A second booster dose (fourth immunization) a year after the primary vaccination further increased the half-life to 88 days. However, despite this modestly improved durability in nAb responses against the ancestral (WA.1) strain, there was a loss of neutralization capacity against the Omicron subvariants BA.2.75.2, BQ.1.1, and XBB.1.5 (48-, 71-, and 66-fold drop in titers, respectively, relative to the WA.1 strain). Although only 45% to 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (third dose), the response declined to below the detection limit in almost all individuals by 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months. CONCLUSION. The durability of serum antibody responses improves only marginally following booster immunizations with the Pfizer-BioNTech or Moderna mRNA vaccines.

Published
2023
Full Text
View/download PDF

11. Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates

Author

Gagne, Matthew, primary, Flynn, Barbara J., additional, Andrew, Shayne F., additional, Flebbe, Dillon R., additional, Mychalowych, Anna, additional, Lamb, Evan, additional, Davis-Gardner, Meredith E., additional, Burnett, Matthew R., additional, Serebryannyy, Leonid A., additional, Lin, Bob C., additional, Pessaint, Laurent, additional, Todd, John-Paul M., additional, Ziff, Zohar E., additional, Maule, Erin, additional, Carroll, Robin, additional, Naisan, Mursal, additional, Jethmalani, Yogita, additional, Case, James Brett, additional, Dmitriev, Igor P., additional, Kashentseva, Elena A., additional, Ying, Baoling, additional, Dodson, Alan, additional, Kouneski, Katelyn, additional, Doria-Rose, Nicole A., additional, O'Dell, Sijy, additional, Godbole, Sucheta, additional, Laboune, Farida, additional, Henry, Amy R., additional, Marquez, Josue, additional, Teng, I-Ting, additional, Wang, Lingshu, additional, Zhou, Qiong, additional, Wali, Bushra, additional, Ellis, Madison, additional, Zouantchangadou, Serge, additional, Van Ry, Alex, additional, Lewis, Mark G., additional, Andersen, Hanne, additional, Kwong, Peter D., additional, Curiel, David T., additional, Foulds, Kathryn E., additional, Nason, Martha C., additional, Suthar, Mehul S., additional, Roederer, Mario, additional, Diamond, Michael S., additional, Douek, Daniel C., additional, and Seder, Robert A., additional

Published
2023
Full Text
View/download PDF

12. Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

Author

Suthar, Mehul, primary, Moreno, Alberto, additional, Manning, Kelly, additional, Azeem, Maryam, additional, Nooka, Ajay, additional, Ellis, Madison, additional, Manalo, Renee, additional, Switchenko, Jeffrey, additional, Wali, Bushra, additional, Kaufman, Jonathan, additional, Hofmeister, Craig, additional, Joseph, Nisha, additional, Lonial, Sagar, additional, Dhodapkar, Kavita, additional, and Dhodapkar, Madhav, additional

Published
2023
Full Text
View/download PDF

13. AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.

Author

Grigoryan, Lilit, Feng, Yupeng, Bellusci, Lorenza, Lai, Lilin, Wali, Bushra, Ellis, Madison, Yuan, Meng, Arunachalam, Prabhu S., Hu, Mengyun, Kowli, Sangeeta, Gupta, Sheena, Maysel-Auslender, Sofia, Maecker, Holden T., Samaha, Hady, Rouphael, Nadine, Wilson, Ian A., Moreno, Alberto C., Suthar, Mehul S., Khurana, Surender, and Pillet, Stéphane

Subjects
IMMUNOLOGIC memory, COVID-19 pandemic, COVID-19 vaccines, VIRUS-like particles, MESSENGER RNA
Abstract

Vaccine adjuvants increase the breadth of serum antibody responses, but whether this is due to the generation of antigen-specific B cell clones with distinct specificities or the maturation of memory B cell clones that produce broadly cross-reactive antibodies is unknown. Here, we longitudinally analyzed immune responses in healthy adults after two-dose vaccination with either a virus-like particle COVID-19 vaccine (CoVLP), CoVLP adjuvanted with AS03 (CoVLP+AS03), or a messenger RNA vaccination (mRNA-1273). CoVLP+AS03 enhanced the magnitude and durability of circulating antibodies and antigen-specific CD4+ T cell and memory B cell responses. Antigen-specific CD4+ T cells in the CoVLP+AS03 group at day 42 correlated with antigen-specific memory B cells at 6 months. CoVLP+AS03 induced memory B cell responses, which accumulated somatic hypermutations over 6 months, resulting in enhanced neutralization breadth of monoclonal antibodies. Furthermore, the fraction of broadly neutralizing antibodies encoded by memory B cells increased between day 42 and 6 months. These results indicate that AS03 enhances the antigenic breadth of B cell memory at the clonal level and induces progressive maturation of the B cell response. Editor's summary: Adjuvants are known to improve the magnitude, durability, and breadth of the immune response to vaccination, but how they modulate memory B cells is unclear. Grigoryan et al. analyzed immune responses in healthy individuals at multiple time points after two-dose vaccination with a plant-based SARS-CoV-2 vaccine (CoVLP) with or without adjuvant (AS03). AS03 adjuvant induced robust and more persistent RBD-specific memory B cells with increased neutralization breadth. This was due to AS03 promoting the selection of broadly neutralizing memory B cells, which accumulated SHMs over time. These findings highlight the role of adjuvants in enhancing memory B cell responses to vaccination. —Hannah Isles [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity

Author

Moreno, Alberto, primary, Manning, Kelly, additional, Azeem, Maryam I., additional, Nooka, Ajay K., additional, Ellis, Madison, additional, Manalo, Renee Julia, additional, Switchenko, Jeffrey M., additional, Wali, Bushra, additional, Kaufman, Jonathan L., additional, . Hofmeister, Craig C., additional, Joseph, Nisha S., additional, Lonial, Sagar, additional, Dhodapkar, Kavita M., additional, Dhodapkar, Madhav V., additional, and Suthar, Mehul, additional

Published
2023
Full Text
View/download PDF

19. Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies

Author

Chang, Andres, primary, Koff, Jean L., additional, Lai, Lilin, additional, Orellana-Noia, Victor M., additional, Surati, Minal, additional, Leal, Alyssa M. K., additional, Ellis, Madison L., additional, Wali, Bushra, additional, Moreno, Alberto, additional, Linderman, Susanne L., additional, O’Leary, Colin B., additional, Allen, Pamela B., additional, Churnetski, Michael C., additional, Dhodapkar, Madhav V., additional, Suthar, Mehul S., additional, Cohen, Jonathon B., additional, and Ahmed, Rafi, additional

Published
2023
Full Text
View/download PDF

21. Supplementary Table S1 from Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Author

Azeem, Maryam I., primary, Nooka, Ajay K., primary, Shanmugasundaram, Uma, primary, Cheedarla, Narayanaiah, primary, Potdar, Sayalee, primary, Manalo, Renee Julia, primary, Moreno, Alberto, primary, Switchenko, Jeffrey M., primary, Cheedarla, Suneethamma, primary, Doxie, Deon Bryant, primary, Radzievski, Roman, primary, Ellis, Madison Leigh, primary, Manning, Kelly E., primary, Wali, Bushra, primary, Valanparambil, Rajesh M., primary, Maples, Kathryn T., primary, Baymon, Essence, primary, Kaufman, Jonathan L., primary, Hofmeister, Craig C., primary, Joseph, Nisha S., primary, Lonial, Sagar, primary, Roback, John D., primary, Sette, Alessandro, primary, Ahmed, Rafi, primary, Suthar, Mehul S., primary, Neish, Andrew S., primary, Dhodapkar, Madhav V., primary, and Dhodapkar, Kavita M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figures from Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Author

Azeem, Maryam I., primary, Nooka, Ajay K., primary, Shanmugasundaram, Uma, primary, Cheedarla, Narayanaiah, primary, Potdar, Sayalee, primary, Manalo, Renee Julia, primary, Moreno, Alberto, primary, Switchenko, Jeffrey M., primary, Cheedarla, Suneethamma, primary, Doxie, Deon Bryant, primary, Radzievski, Roman, primary, Ellis, Madison Leigh, primary, Manning, Kelly E., primary, Wali, Bushra, primary, Valanparambil, Rajesh M., primary, Maples, Kathryn T., primary, Baymon, Essence, primary, Kaufman, Jonathan L., primary, Hofmeister, Craig C., primary, Joseph, Nisha S., primary, Lonial, Sagar, primary, Roback, John D., primary, Sette, Alessandro, primary, Ahmed, Rafi, primary, Suthar, Mehul S., primary, Neish, Andrew S., primary, Dhodapkar, Madhav V., primary, and Dhodapkar, Kavita M., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables S2-S4 from Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Author

Azeem, Maryam I., primary, Nooka, Ajay K., primary, Shanmugasundaram, Uma, primary, Cheedarla, Narayanaiah, primary, Potdar, Sayalee, primary, Manalo, Renee Julia, primary, Moreno, Alberto, primary, Switchenko, Jeffrey M., primary, Cheedarla, Suneethamma, primary, Doxie, Deon Bryant, primary, Radzievski, Roman, primary, Ellis, Madison Leigh, primary, Manning, Kelly E., primary, Wali, Bushra, primary, Valanparambil, Rajesh M., primary, Maples, Kathryn T., primary, Baymon, Essence, primary, Kaufman, Jonathan L., primary, Hofmeister, Craig C., primary, Joseph, Nisha S., primary, Lonial, Sagar, primary, Roback, John D., primary, Sette, Alessandro, primary, Ahmed, Rafi, primary, Suthar, Mehul S., primary, Neish, Andrew S., primary, Dhodapkar, Madhav V., primary, and Dhodapkar, Kavita M., primary

Published
2023
Full Text
View/download PDF

24. Data from Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Author

Azeem, Maryam I., primary, Nooka, Ajay K., primary, Shanmugasundaram, Uma, primary, Cheedarla, Narayanaiah, primary, Potdar, Sayalee, primary, Manalo, Renee Julia, primary, Moreno, Alberto, primary, Switchenko, Jeffrey M., primary, Cheedarla, Suneethamma, primary, Doxie, Deon Bryant, primary, Radzievski, Roman, primary, Ellis, Madison Leigh, primary, Manning, Kelly E., primary, Wali, Bushra, primary, Valanparambil, Rajesh M., primary, Maples, Kathryn T., primary, Baymon, Essence, primary, Kaufman, Jonathan L., primary, Hofmeister, Craig C., primary, Joseph, Nisha S., primary, Lonial, Sagar, primary, Roback, John D., primary, Sette, Alessandro, primary, Ahmed, Rafi, primary, Suthar, Mehul S., primary, Neish, Andrew S., primary, Dhodapkar, Madhav V., primary, and Dhodapkar, Kavita M., primary

Published
2023
Full Text
View/download PDF

25. Durability of immune responses to the booster mRNA vaccination against COVID-19

Author

Arunachalam, Prabhu S, primary, Lai, Lilin, additional, Samaha, Hady, additional, Feng, Yupeng, additional, Hu, Mengyun, additional, Hui, Harold Sai-yin, additional, Wali, Bushra, additional, Ellis, Madison L., additional, Davis-Gardner, Meredith E., additional, Huerta, Christopher M., additional, Bechnak, Kareem, additional, Bechnak, Sarah, additional, Lee, Matthew, additional, Litvack, Matthew B., additional, Losada, Cecilia, additional, Grifoni, Alba, additional, Sette, Alessandro, additional, Zarnitsyna, Veronika I., additional, Rouphael, Nadine, additional, Suthar, Mehul S., additional, and Pulendran, Bali, additional

Published
2023
Full Text
View/download PDF

26. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

Author

Davis-Gardner, Meredith E., primary, Lai, Lilin, additional, Wali, Bushra, additional, Samaha, Hady, additional, Solis, Daniel, additional, Lee, Matthew, additional, Porter-Morrison, Andrea, additional, Hentenaar, Ian T., additional, Yamamoto, Fumiko, additional, Godbole, Sucheta, additional, Liu, Yuan, additional, Douek, Daniel C., additional, Lee, Frances Eun-Hyung, additional, Rouphael, Nadine, additional, Moreno, Alberto, additional, Pinsky, Benjamin A., additional, and Suthar, Mehul S., additional

Published
2023
Full Text
View/download PDF

27. Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

Author

Azeem, Maryam I., primary, Nooka, Ajay K., additional, Shanmugasundaram, Uma, additional, Cheedarla, Narayanaiah, additional, Potdar, Sayalee, additional, Manalo, Renee Julia, additional, Moreno, Alberto, additional, Switchenko, Jeffrey M., additional, Cheedarla, Suneethamma, additional, Doxie, Deon Bryant, additional, Radzievski, Roman, additional, Ellis, Madison Leigh, additional, Manning, Kelly E., additional, Wali, Bushra, additional, Valanparambil, Rajesh M., additional, Maples, Kathryn T., additional, Baymon, Essence, additional, Kaufman, Jonathan L., additional, Hofmeister, Craig C., additional, Joseph, Nisha S., additional, Lonial, Sagar, additional, Roback, John D., additional, Sette, Alessandro, additional, Ahmed, Rafi, additional, Suthar, Mehul S., additional, Neish, Andrew S., additional, Dhodapkar, Madhav V., additional, and Dhodapkar, Kavita M., additional

Published
2022
Full Text
View/download PDF

28. Durability of immune responses to the booster mRNA vaccination against COVID-19

Author

Arunachalam, Prabhu S., primary, Lai, Lilin, additional, Samaha, Hady, additional, Feng, Yupeng, additional, Hu, Mengyun, additional, Hui, Harold Sai-yin, additional, Wali, Bushra, additional, Ellis, Madison, additional, Huerta, Christopher, additional, Bechnack, Kareem, additional, Bechnack, Sarah, additional, Lee, Matthew, additional, Litvack, Matthew, additional, Losada, Cecilia, additional, Grifoni, Alba, additional, Sette, Alessandro, additional, Zarnitsyna, Veronika I., additional, Rouphael, Nadine, additional, Suthar, Mehul S., additional, and Pulendran, Bali, additional

Published
2022
Full Text
View/download PDF

29. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1

Author

Davis-Gardner, Meredith E., primary, Lai, Lilin, additional, Wali, Bushra, additional, Samaha, Hady, additional, Solis, Daniel, additional, Lee, Matthew, additional, Porter-Morrison, Andrea, additional, Hentenaar, Ian Thomas, additional, Yamamoto, Fumiko, additional, Godbole, Sucheta, additional, Douek, Daniel C., additional, Lee, Frances Eun-Hyung, additional, Rouphael, Nadine, additional, Moreno, Alberto, additional, Pinsky, Benjamin A., additional, and Suthar, Mehul S., additional

Published
2022
Full Text
View/download PDF

32. Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in children: A pilot study

Author

Reisner, Andrew, primary, Blackwell, Laura S, additional, Sayeed, Iqbal, additional, Myers, Hannah E, additional, Wali, Bushra, additional, Heilman, Stacy, additional, Figueroa, Janet, additional, Lu, Austin, additional, Hussaini, Laila, additional, Anderson, Evan J, additional, Shane, Andi L, additional, and Rostad, Christina A, additional

Published
2021
Full Text
View/download PDF

39. On the Limitations of Progesterone Treatment in Very Severe Traumatic Brain Injury: What Can Be Learned from Allitt et al., “Progesterone Exacerbates Short-Term Effects of Traumatic Brain Injury”

Author

Atif, Fahim, primary, Espinosa-Garcia, Claudia, additional, Sayeed, Iqbal, additional, Sergeeva, Elena G., additional, Turan, Nefize, additional, Wali, Bushra, additional, Wright, David W., additional, Yousuf, Seema, additional, and Stein, Donald G., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results